164 related articles for article (PubMed ID: 35352474)
1. Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia.
Kubo M; Sakai K; Hayakawa M; Kashiwagi H; Yagi H; Seki Y; Hasegawa A; Tanaka H; Amano I; Tomiyama Y; Matsumoto M
J Thromb Haemost; 2022 Jul; 20(7):1589-1598. PubMed ID: 35352474
[TBL] [Abstract][Full Text] [Related]
2. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count.
Lancellotti S; Dragani A; Ranalli P; Petrucci G; Basso M; Tartaglione R; Rocca B; De Cristofaro R
J Thromb Haemost; 2015 Jul; 13(7):1226-37. PubMed ID: 25876231
[TBL] [Abstract][Full Text] [Related]
3. Blood group antigen A on von Willebrand factor is more protective against ADAMTS13 cleavage than antigens B and H.
Hayakawa M; Kato S; Matsui T; Sakai K; Fujimura Y; Matsumoto M
J Thromb Haemost; 2019 Jun; 17(6):975-983. PubMed ID: 30929293
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia.
Janjetovic S; Rolling CC; Budde U; Schneppenhem S; Schafhausen P; Peters MC; Bokemeyer C; Holstein K; Langer F
Thromb Res; 2022 Oct; 218():35-43. PubMed ID: 35988442
[TBL] [Abstract][Full Text] [Related]
5. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
[TBL] [Abstract][Full Text] [Related]
6. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
Matsuyama T; Uemura M; Ishikawa M; Matsumoto M; Ishizashi H; Kato S; Morioka C; Fujimoto M; Kojima H; Yoshiji H; Takimura C; Fujimura Y; Fukui H
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S27-35. PubMed ID: 17331163
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the ADAMTS13-VWF axis in acute Kawasaki disease and effects of intravenous immunoglobulin.
Tsujii N; Nogami K; Matsumoto M; Yoshizawa H; Takase T; Tanaka I; Sakai T; Fukuda K; Hayakawa M; Sakai K; Isonishi A; Matsuura K; Fujimura Y; Shima M
Thromb Res; 2019 Jul; 179():1-10. PubMed ID: 31055186
[TBL] [Abstract][Full Text] [Related]
8. Thrombocytapheresis for acquired von Willebrand syndrome in a patient with essential thrombocythemia and recent multivisceral transplantation.
Oyedeji O; Sheqwara J; Onwubiko I; Lopez-Plaza I; Nagai S; Otrock ZK
Transfusion; 2021 Nov; 61(11):3277-3280. PubMed ID: 34569071
[TBL] [Abstract][Full Text] [Related]
9. ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantation.
Deconinck SJ; Nix C; Barth S; Bennek-Schöpping E; Rauch A; Schelpe AS; Roose E; Feys HB; Pareyn I; Vandenbulcke A; Muia J; Vandenbriele C; Susen S; Meyns B; Tersteeg C; Jacobs S; De Meyer SF; Vanhoorelbeke K
J Thromb Haemost; 2022 Dec; 20(12):2797-2809. PubMed ID: 36128768
[TBL] [Abstract][Full Text] [Related]
10. [Successful management of intraperitoneal bleeding with platelet apheresis and von Willebrand factor supplementation in a patient with essential thrombocythemia and acquired von Willebrand syndrome].
Ueki T; Takeshige K; Sumi M; Ueno M; Ichikawa N; Kobayashi H
Rinsho Ketsueki; 2017; 58(8):922-926. PubMed ID: 28883275
[TBL] [Abstract][Full Text] [Related]
11. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
[TBL] [Abstract][Full Text] [Related]
12. Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W.
Pruss CM; Golder M; Bryant A; Hegadorn C; Haberichter S; Lillicrap D
J Thromb Haemost; 2012 May; 10(5):940-50. PubMed ID: 22372972
[TBL] [Abstract][Full Text] [Related]
13. Establishing a method for in vitro investigation of mechanical parameters causing acquired von Willebrand syndrome in ventricular assist devices.
Egger C; Maas J; Hufen T; Schmitz-Rode T; Steinseifer U
Artif Organs; 2013 Sep; 37(9):833-9. PubMed ID: 23834027
[TBL] [Abstract][Full Text] [Related]
14. Acquired Von Willebrand syndrome in patients on long-term support with HeartMate II.
Heilmann C; Trummer G; Beyersdorf F; Brehm K; Berchtold-Herz M; Schelling J; Geisen U; Zieger B
Eur J Cardiothorac Surg; 2017 Mar; 51(3):587-590. PubMed ID: 28082469
[TBL] [Abstract][Full Text] [Related]
15. Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.
Rauch A; Legendre P; Christophe OD; Goudemand J; van Belle E; Vincentelli A; Denis CV; Susen S; Lenting PJ
Thromb Haemost; 2014 Nov; 112(5):1014-23. PubMed ID: 25030452
[TBL] [Abstract][Full Text] [Related]
16. Reduced larger von Willebrand factor multimers at dawn in OSA plasmas reflect severity of apnoeic episodes.
Koyama N; Matsumoto M; Tamaki S; Yoshikawa M; Fujimura Y; Kimura H
Eur Respir J; 2012 Sep; 40(3):657-64. PubMed ID: 22362856
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.
Stufano F; Boscarino M; Bucciarelli P; Baronciani L; Maino A; Cozzi G; Peyvandi F
Semin Thromb Hemost; 2019 Feb; 45(1):36-42. PubMed ID: 29913537
[TBL] [Abstract][Full Text] [Related]
18. [Acquired von Willebrand syndrome].
Hayakawa M; Matsumoto M
Rinsho Ketsueki; 2020; 61(7):809-817. PubMed ID: 32759569
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.
Tiede A; Priesack J; Werwitzke S; Bohlmann K; Oortwijn B; Lenting P; Eisert R; Ganser A; Budde U
J Thromb Haemost; 2008 Apr; 6(4):569-76. PubMed ID: 18208537
[TBL] [Abstract][Full Text] [Related]
20. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
Budde U; Schneppenheim R
Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
